At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Colchicine Cardiovascular Outcomes Trial (COLCOT)
In Brief
A Phase 3 clinical trial evaluating colchicine and colchicine placebo for Coronary Artery Disease and Myocardial Infarction. Completed, enrolled 4,745 participants across 1 site.
Detailed Summary
The study evaluates whether long-term treatment with colchicine reduces rates of cardiovascular events in patients after myocardial infarction. Patients who have suffered a documented acute myocardial infarction within the last 30 days, are treated according to the national guidelines and after having completed any planned percutaneous revascularization procedures associated with their initial infarction will receive either colchicine (0.5 mg per day) or matching placebo (1:1 allocation ratio) for an estimated 2 years period or until the target of 301 primary endpoints has been reached.
Study Details
Timeline
Interventions
0.5 mg tablet taken once a day
sugar pill manufactured to mimic colchicine 0.5 mg tablet